Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in ChinaPuyuan Xing, Junling Li, Tao Xin et al.|Targeted Oncology|2019Cited by 14
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort studyPuyuan Xing, Junling Li, Tao Xin et al.|Chinese Journal of Cancer Research|2019Cited by 9
Clinical features and outcomes of<i>ALK</i>rearranged non‐small cell lung cancer with primary resistance to crizotinibDi Ma, Junling Li, Zhaohui Zhang et al.|Thoracic Cancer|2019Cited by 6
<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>Hongge Liang, Mengzhao Wang, Minjiang Chen et al.|Cancer Management and Research|2019Cited by 6